摘要
目的观察化痰消脂方对慢性乙型肝炎(CHB)并发非酒精性脂肪性肝病(NAFLD)患者干扰素抗病毒治疗疗效的影响,并探讨其相关机制。方法随机将62例患者分成治疗组和对照组,各31例。治疗组给予化痰消脂方联合干扰素治疗,对照组单用干扰素治疗,观察两组患者治疗前后HOMA-IR、HBVDNA定量、HBV-M的变化及超声显示的脂肪肝改善情况。结果治疗组患者脂肪肝改善率、病毒应答率明显高于对照组(P<0.01或P<0.05),HOMA-IR明显降低(P<0.01)。结论化痰消脂方能明显提高CHB并发NAFLD患者的抗病毒应答率,其机制可能与改善此类患者脂肪肝及胰岛素抵抗状况有关。
Objective To observe whether Huatanxiaozhi decoction can impact the efficacy of antiviral therapy of chronic hepatitis B （CHB） patients who concurrently suffered from NAFLD. Methods Total of 62 patients were randomly divided into two groups： control group （n = 31） and treatment group （n = 31）. The patients in the control group were treated with interferon only, while the others with interferon plus Huatanxiaozhi decoction. The serum parameters, such as HBV marker, level of HBV DNA, HOMA-IR were analysed, and the improvement of fatty liver in ultrasound were observed. Results Compared with the control group, the rate of fatty liver improvement and the virus response is much higher in the treatment group （P 0.01 or P 0.05）, while the level of HOMA-IR reduced significantly （P 0.01）. Conclusions Huatanxiaozhi decoction can promote the viral response rate of chronic hepatitis B patients who concurrently suffered from NAFLD, the probable mechanism is its positive effect on insulin resistance （IR） which made the fatty liver improved.
出处
《中国肝脏病杂志（电子版）》
CAS
2012年第1期16-19,共4页
Chinese Journal of Liver Diseases：Electronic Version
基金
深圳市科技计划项目(201003135)
关键词
治疗应用
肝炎
乙型
慢性
脂肪肝
酒精性
Therapeutic use
Hepatitis B
chronic
Fatty liver
alcoholic
